Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changzheng Xinkai’s Ainuohua Gets SFDA Approval For Treating Lupus Nephritis

This article was originally published in PharmAsia News

Executive Summary

Suzhou Changzheng Xinkai Pharmaceutical has received China's State FDA approval for its Ainuohua (leflunomide tablets), representing the first drug for the treatment of lupus nephritis to be launched in China. In 2000, Changzheng Xinkai applied to expand the drug's indication for adult rheumatic arthritis to lupus nephritis. In 2002, Peking University First Hospital and nine other authoritative healthcare institutions launched a five-year multicenter, controlled clinical trial. The trial results show that Ainuohua achieved an overall response rate of 80 percent in relieving lupus nephritis, effectively reduced 24-hour urine protein and Systemic Lupus Erythematosus Disease Activity Index score, and increased serum albumin and complement level. Particularly noteworthy is the drug's safety and ability to reverse some patients' renal pathological changes. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071450

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel